Spotlight On… Medidata buys out Intelemage; Pharm-Olam appoints new exec; and more…

large can lights shining down

The New York, cloud-based clinical research solutions team Medidata ($MDSO) has acquired the Cincinnati, OH-headquartered Intelemage as it looks to expand its medical imaging services. Medidata will integrate Intelemage's technology into its Clinical Cloud program, offering customers what it calls "an end-to-end solution to capture, manage and analyze medical imaging data." Founded in 2007, Intelemage uses medical image file sharing in clinical trials as well as for hospitals, doctors, life science companies, research institutions and core labs. The company also provides tools for medical imaging data capture and workflow management. This follows a spate of deals for Medidata that includes tie-ups with Apple's ($AAPL) ResearchKit and broadening its geographical reach with a recent collaboration in South Korea. Financial details of the Intelemage deal were not disclosed. Release

> Houston, TX-based CRO Pharm-Olam International has appointed Tricia Bland to its management team as its new executive director of strategic projects. Release

> The EMA has said it will review a number of medicines for which studies have been conducted at the Alkem Laboratories site in Taloja, India, where the company tests the bioequivalence of its generics. This follows a recent GCP inspection of the site that raised concerns regarding study data used to support the drug applications of some medicines in the EU. Release


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.